MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Kura Oncology Inc

Cerrado

SectorSalud

5.7 -7.17

Resumen

Variación precio

24h

Actual

Mínimo

5.7

Máximo

5.91

Métricas clave

By Trading Economics

Ingresos

35M

-19M

Ventas

54M

54M

BPA

-0.22

Margen de beneficio

-35.664

Empleados

192

EBITDA

43M

-17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+325.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-43M

570M

Apertura anterior

12.87

Cierre anterior

5.7

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

156 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

5 abr 2025, 09:30 UTC

Ganancias

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

5 abr 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 abr 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 abr 2025, 21:53 UTC

Charlas de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 abr 2025, 21:44 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 abr 2025, 21:00 UTC

Principales Noticias

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 abr 2025, 20:52 UTC

Charlas de Mercado

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 abr 2025, 20:52 UTC

Principales Noticias

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 abr 2025, 20:48 UTC

Principales Noticias

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 abr 2025, 20:45 UTC

Principales Noticias

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 abr 2025, 20:32 UTC

Principales Noticias

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 abr 2025, 20:21 UTC

Principales Noticias

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 abr 2025, 20:00 UTC

Principales Noticias

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 abr 2025, 19:51 UTC

Charlas de Mercado

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 abr 2025, 19:37 UTC

Principales Noticias

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 abr 2025, 19:32 UTC

Charlas de Mercado

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 abr 2025, 19:28 UTC

Principales Noticias

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 abr 2025, 19:15 UTC

Charlas de Mercado

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 abr 2025, 19:12 UTC

Principales Noticias

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 abr 2025, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 abr 2025, 19:09 UTC

Charlas de Mercado

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 abr 2025, 19:09 UTC

Principales Noticias

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 abr 2025, 19:00 UTC

Charlas de Mercado

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 abr 2025, 18:53 UTC

Charlas de Mercado

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 abr 2025, 18:51 UTC

Charlas de Mercado

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 abr 2025, 18:44 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 abr 2025, 18:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 abr 2025, 18:44 UTC

Charlas de Mercado

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc Esperado

Precio Objetivo

By TipRanks

325.45% repunte

Estimación a 12 meses

Media 26.25 USD  325.45%

Máximo 40 USD

Mínimo 10 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

12

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 6.27Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

156 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.